However, our main focuses were gemcitabine- NF-κB -Bfl-1 axis implicated in low gemcitabine resistance of lung cancer cells, and the utility of BC to overcome gemcitabine resistance in this system. This evidence concerns the gene BCL2A1 and breast cancer.